Plain-English translation of NCT07241117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The CHEST study is testing whether doctors and clinics can better manage moderate to severe asthma by implementing SMART (Symbicort Maintenance and Reliever Therapy) prescribing practices. SMART is a treatment approach where patients use one inhaler for both daily control and quick relief of symptoms. The study will provide doctors with training, feedback on their prescribing patterns, and patient-friendly educational materials to help them adopt this approach.
Many patients with moderate to severe asthma don't receive the best possible treatment, and doctors may not be aware of the most current, evidence-based prescribing guidelines. This study aims to improve asthma control and reduce flare-ups by helping community health center doctors learn and use this more effective treatment strategy.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctor and clinic will receive training on the new SMART approach during the active implementation phase, which typically lasts 9 to 24 months. You will continue receiving regular asthma care at your clinic and may receive new educational materials and an updated asthma action plan. The study team will track your asthma prescription patterns and outcomes, but your doctor remains free to make their own prescribing decisions based on your individual needs.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States